Bioventus Inc.

NASDAQ:BVS

Medical - Devices

Healthcare
$10.62 +2.11%

+$0.18 today

Market cap
$727.20M
Beta
0.67
P/E (TTM)
20.6
EPS (TTM)
$0.42
52W Low $5.81High $11.25

Volume 0.70M

Average 0.56M

BVS Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Bioventus Inc.NASDAQ: BVS

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation grows in line with its trailing trend

Q1 FY2026 stock-based compensation of $3.26M rose 35.2% year over year, behind the +36.9% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 5.1% from the prior quarter. Over 3 fiscal years it compounded at -10.3% a year.

Context

  • Stock-based compensation amounted to 2.2% of revenue in FY2025, up 0.5 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +35.2% toward the trailing-twelve-month pace of +36.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.26M-5.1% QoQ
Last fiscal yearDec 2025
$12.67M+26.0% YoY
LTMMar 2026
$13.52M+36.9% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+35.2%——
1 year+26.0%——
3-year CAGR-10.3%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
12.67M USD
Year-over-year change
+26.0%
4-year CAGR
-10.6%

Stock-Based Compensation vs competitors

How BVS compares with its peers on the latest reported figures

  • BVS's LTM Mar 2026 stock-based compensation of $13.52M is the 7th largest of the 9 companies compared; the peer median is $14.28M.
  • Its year-over-year change of +36.9% is the 2nd highest of 9, against a peer median of +6.7%.
  • Stock-based compensation amounts to 2.3% of revenue for BVS, versus a peer median of 3.2%.
BVS Competitors Peer median
Stock-Based Compensation for BVS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SNNSmith & Nephew plcFY2025$43M +7.5%+2.4%0.7%
OFIXOrthofix Medical Inc.LTM Mar 2026$42.3M +40.4%+15.9%5.1%
IARTIntegra LifeSciences Holdings CorporationLTM Mar 2026$21.88M +6.0%-12.5%1.3%
MDXGMiMedx Group, Inc.LTM Mar 2026$14.7M -12.8%+13.1%3.8%
ANIKAnika Therapeutics, Inc.LTM Mar 2026$13.86M +11.8%-11.0%11.9%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$13.57M +17.6%+26.6%2.6%
BVSBioventus Inc.LTM Mar 2026$13.52M +36.9%-10.3%2.3%
TELATELA Bio, Inc.LTM Jun 2026$3.2M -23.9%-1.6%4.0%
XTNTXtant Medical Holdings, Inc.LTM Mar 2026$2.88M -27.4%+5.5%2.4%
Peer median (excluding BVS) $14.28M+6.7%+4.0%3.2%

Competitors are the stored peer set for BVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income11.45M(144.65M)(121.2M)(318K)27.27M
Depreciation & Amortization34.88M55.4M57.37M49.56M47.01M
Deferred Income Tax(9.76M)(46.66M)(2.38M)(5.39M)(909K)
Stock-Based Compensation19.84M17.59M2.72M10.06M12.67M
Change in Working Capital(15.15M)(29.73M)(3.18M)(11.78M)(13.84M)
Accounts Receivables(20.05M)(17.67M)10.06M(10.67M)(916K)
Inventory3.18M(18.62M)(5.99M)(16.44M)8.57M
Accounts Payables0000(19.81M)
Other Working Capital1.72M6.56M(13.24M)15.32M(1.68M)
Other Non-Cash Items(18.28M)134.52M82.01M(3.33M)1.77M
Operating Cash Flow22.99M(13.54M)15.34M38.8M73.98M
Capital Expenditures(20.89M)(1.48M)(7.36M)(1.01M)(2.56M)
Acquisitions (Net)(262.87M)034.68M0(686K)
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(7.37M)(114.96M)(11.51M)23.97M0
Investing Cash Flow(283.76M)(116.44M)15.81M22.96M(3.25M)
Debt Repayment166.2M59.62M(23.26M)(59.58M)(42.91M)
Common Stock Issued109.41M5.82M778K2.44M2.07M
Common Stock Repurchased00000
Dividends Paid(367K)0000
Other Financing Activities(1.88M)(3.37M)(4.17M)2.56M(20.61M)
Financing Cash Flow273.37M62.08M(26.65M)(54.58M)(61.44M)
Effect of Forex Changes(228K)521K629K(2.56M)371K
Net Change in Cash12.37M(67.38M)5.13M4.62M9.66M
Free Cash Flow2.1M(15.02M)7.98M37.79M71.41M

Bioventus Inc.

NASDAQ:BVS

Intrinsic Alpha fair value

Locked

Current Price

$10.62

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.